Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: Risk factors and survival

Chinese Journal of Cancer

Volumn 34, Issue 5, 2015, Pages

  Chen, Kai Lin ^a   Chen, Jie ^b   Rao, Hui Lan ^a   Guo, Ying ^a   Huang, Hui Qiang ^a   Zhang, Liang ^c   Shao, Jian Yong ^a   Lin, Tong Yu ^a   Jiang, Wen Qi ^a   Zou, De Hui ^d,e   Hu, Li Yang ^a   Wirian, Michael Lucas ^a   Cai, Qing Qing ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^e PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Diffuse large B cell lymphoma; Hepatitis; Hepatitis B virus reactivation; Resolved hepatitis B

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE; HEPATITIS B ANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; CHILD; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LARGE CELL LYMPHOMA; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; RISK FACTOR; TUMOR GROWTH; VIRUS REACTIVATION; CHINA; DIFFUSE LARGE B CELL LYMPHOMA; MORTALITY; PROGNOSIS; VIRUS ACTIVATION;

CHINA; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MORTALITY; PROGNOSIS; RISK FACTORS; RITUXIMAB; VIRUS ACTIVATION;

EID: 84935843497     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.1186/s40880-015-0015-9     Document Type: Article

References (41)

1. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337: 1733-45.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002; 346: 235-42.
3. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by MabThera International Trial (MInT) Group. Lancet Oncol. 2006; 7: 379-91.
4. Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009; 27: 605-11.
5. Shih LN, Sheu JC, Wang JT, Huang GT, Yang PM, Lee HS, et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol. 1990; 32: 257-60.
6. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol. 2011; 22: 1170-80.
7. Pei SN, Chen CH, Lee CM, Wang MC, Ma MC, Hu TH, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010; 89: 255-62.
8. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57: 167-85.
9. Hui CK, Cheung WW, Zhang HY, Au WY, Yueng YH, Leung AY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006; 131: 59-68.
10. Koo YX, Tay M, Teh YE, Teng D, Tan DS, Tan IB, et al. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis. Ann Hematol. 2011; 90: 1219-23.
11. Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009; 20: 2013-7.
12. Ji D, Cao J, Hong X, Li J, Wang J, Chen F, et al. Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/HBcAb-positive: a multicenter retrospective study. Eur J Haematol. 2010; 85: 243-50.
13. Matsue K, Kimura S, Takanashi Y, Iwama K, Fujiwara H, Yamakura M, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010; 116: 4769-76.
14. Swerdlow SHCE, Harris NL, Jaffe ES, Stein H, Thiele J, et al. World health organization classification of tumours of the haematopoietic and lymphoid tissues. Pileri SA: IARC Press; 2008.
15. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004; 22: 927-34.
16. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991; 100: 182-8.
17. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28: 2373-80.
18. Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34: 187-220.
19. Marcucci F, Mele A, Spada E, Candido A, Bianco E, Pulsoni A, et al. High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. Haematologica. 2006; 91: 554-7.
20. Wang F, Xu RH, Han B, Shi YX, Luo HY, Jiang WQ, et al. High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer. 2007; 109: 1360-4.
21. Kim JH, Bang YJ, Park BJ, Yoo T, Kim CW, Kim TY, et al. Hepatitis B virus infection and B-cell non-Hodgkin's lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res. 2002; 93: 471-7.
22. Qin XT, Lu Y, Chen XQ, Xu HP, Fan HJ. Correlation of hepatitis B virus infection to non-Hodgkin's lymphoma. Chin J Cancer. 2007; 26: 294-7.
23. Engels EA, Cho ER, Jee SH. Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol. 2010; 11: 827-34.
24. Wang F, Yuan S, Teng KY, Garcia-Prieto C, Luo HY, Zeng MS, et al. High hepatitis B virus infection in B-cell lymphoma tissue and its potential clinical relevance. Eur J Cancer Prev. 2012; 21: 261-7.
25. Marzano A, Angelucci E, Andreone P, Brunetto M, Bruno R, Burra P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis. 2007; 39: 397-408.
26. Hoofnagle JH. Reactivation of hepatitis B. Hepatology. 2009; 49: S156-65.
27. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat. 2011; 18: 877-83.
28. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. Chemotherapyinduced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014; 59: 2092-100.
29. Chemin I, Jeantet D, Kay A, Trepo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen(−) liver disease. Antiviral Res. 2001; 52: 117-23.
30. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology. 2008; 245: 194-205.
31. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98: 960-7.
32. Stasi R, Del Poeta G, Stipa E, Evangelista ML, Trawinska MM, Cooper N, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110: 2924-30.
33. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol. 2004; 83: 769-74.
34. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, et al. Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf. 2005; 4: 599-608.
35. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother. 2005; 11: 189-91.
36. Li YH, He YF, Wang FH, Lin XB, Xia ZJ, Sun XF, et al. Clinical analysis of liver damage of 116 malignant lymphoma patients with chronic HBV infection after cytotoxic chemotherapy. Chin J Cancer. 2005; 24: 1507-9.
37. Koo YX, Tan DS, Tan IB, Tao M, Chow WC, Lim ST. Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy. Cancer. 2010; 116: 115-21.
38. Chinese Society of Hematology, CMA, Committee of Malignant Lymphoma, Chinese Anti-cancer Association, Chinese Society of Hepatology, CMA. Consensus on the management of lymphoma with HBV infection. Zhonghua Xue Ye Xue Za Zhi. 2013; 34: 988-93 [in Chinese].
39. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125: 1714-22.
40. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013; 31: 2765-72.
41. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F, et al. Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan. Ann Oncol. 1997; 8 Suppl 1: 107-9.